
HCA Healthcare, Inc. ownership: holders and insider trading
$499.05−0.32%Close 13 Nov 2026 · Market value $107.0B
As filed, its directors and officers own 1.5% of the shares (proxy statement, 23 Feb 2026); 1,331 institutional managers reported holding 63.8% at 30 Jun 2026. Over the last twelve months, insiders sold $29.87M of shares on the open market, and bought none.
From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.
Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|
| Thomas F. Frist III | Insider · active | 70.5M | 33.8% | Schedule 13D | 6 Nov 2026 |
|---|
| Frisco Holding II | Holder | 38.9M | 17.4% | Proxy statement | 23 Feb 2026 |
|---|
| Hercules Holding II | Holder | 34.6M | 15.5% | Proxy statement | 23 Feb 2026 |
|---|
| The Vanguard Group | Holder | 14.5M | 6.87%* | Form 13F | 30 Jun 2026 |
|---|
| BlackRock | Institution | 13.0M | 6.17%* | Form 13F | 30 Jun 2026 |
|---|
| Vanguard Capital Management | Holder | 11.7M | 5.25% | Schedule 13G | 31 Mar 2026 |
|---|
| Sanders Capital, LLC | Institution | 8.8M | 4.19%* | Form 13F | 30 Jun 2026 |
|---|
| State Street | Institution | 7.5M | 3.54%* | Form 13F | 30 Jun 2026 |
|---|
| First Eagle Investment Management, LLC | Institution | 6.6M | 3.13%* | Form 13F | 30 Jun 2026 |
|---|
| Wellington Management | Institution | 4.7M | 2.23%* | Form 13F | 30 Jun 2026 |
|---|
| Capital Group | Institution | 3.9M | 1.85%* | Form 13F | 30 Jun 2026 |
|---|
| Geode Capital Management | Institution | 3.7M | 1.74%* | Form 13F | 30 Jun 2026 |
|---|
| Morgan Stanley | Institution | 2.6M | 1.23%* | Form 13F | 30 Jun 2026 |
|---|
| Goldman Sachs | Institution | 2.5M | 1.17%* | Form 13F | 30 Jun 2026 |
|---|
| JPMorgan Chase | Institution | 2.3M | 1.08%* | Form 13F | 30 Jun 2026 |
|---|
| Arrowstreet Capital, Limited Partnership | Institution | 2.2M | 1.05%* | Form 13F | 30 Jun 2026 |
|---|
| Samuel N. Hazen | Insider | 2.2M | < 1% | Proxy statement | 23 Feb 2026 |
|---|
| Norges Bank | Institution | 2.1M | 1.02%* | Form 13F | 30 Jun 2026 |
|---|
| UBS | Institution | 1.8M | 0.87%* | Form 13F | 30 Jun 2026 |
|---|
| Northern Trust | Institution | 1.7M | 0.81%* | Form 13F | 30 Jun 2026 |
|---|
Insider transactions latest 25
| Insider | Date | Transaction | Shares | Price | Value |
|---|
| Schlosser Michael J · EVP and Chief Clinical Officer | 4 Nov 2026 | Open-market sale | −1.2K | $494.65 | $593.6K |
|---|
| Marks Mike A · EVP and CFO | 30 Oct 2026 | Option exercise | +4.6K | $81.96 | $375.8K |
|---|
| Marks Mike A · EVP and CFO | 30 Oct 2026 | Shares withheld for tax | −2.3K | $473.19 | $1.08M |
|---|
| Schlosser Michael J · EVP and Chief Clinical Officer | 29 Oct 2026 | Option exercise | +3.0K | $81.96 | $248.3K |
|---|
| Schlosser Michael J · EVP and Chief Clinical Officer | 29 Oct 2026 | Option exercise | +1.9K | $82.85 | $157.2K |
|---|
| Schlosser Michael J · EVP and Chief Clinical Officer | 29 Oct 2026 | Shares withheld for tax | −2.5K | $478.08 | $1.17M |
|---|
| Smith Andrea B · Director | 28 Apr 2026 | Grant or award | +509 | — | — |
|---|
| Riley Wayne Joseph · Director | 28 Apr 2026 | Grant or award | +509 | — | — |
|---|
| MICHELSON MICHAEL W · Director | 28 Apr 2026 | Grant or award | +925 | — | — |
|---|
| Johnston Hugh F · Director | 28 Apr 2026 | Grant or award | +809 | — | — |
|---|
| DEPARLE NANCY ANN · Director | 28 Apr 2026 | Grant or award | +509 | — | — |
|---|
| CHIDSEY JOHN · Director | 28 Apr 2026 | Grant or award | +809 | — | — |
|---|
| Frist William R · Director · 10% owner | 28 Apr 2026 | Grant or award | +809 | — | — |
|---|
| FRIST THOMAS F III · Director · 10% owner | 28 Apr 2026 | Grant or award | +1.0K | — | — |
|---|
| McAlevey Michael R · EVP & Chief Legal & Admin Off. | 18 Feb 2026 | Open-market sale | −1.7K | $533.37 | $903.5K |
|---|
| McAlevey Michael R · EVP & Chief Legal & Admin Off. | 13 Feb 2026 | Shares withheld for tax | −3.3K | $540.29 | $1.79M |
|---|
| McAlevey Michael R · EVP & Chief Legal & Admin Off. | 13 Feb 2026 | Option exercise | +5.0K | $236.61 | $1.18M |
|---|
| Wyatt Christopher F. · SVP & Controller | 11 Feb 2026 | Open-market sale | −4.0K | $505.00 | $2.02M |
|---|
| Berres Jennifer · SVP & Chief Human Res. Officer | 11 Feb 2026 | Open-market sale | −4.0K | $526.16 | $2.11M |
|---|
| Berres Jennifer · SVP & Chief Human Res. Officer | 11 Feb 2026 | Open-market sale | −4.0K | $503.00 | $2.02M |
|---|
| Wyatt Christopher F. · SVP & Controller | 10 Feb 2026 | Grant or award | +3.4K | — | — |
|---|
| Wyatt Christopher F. · SVP & Controller | 10 Feb 2026 | Shares withheld for tax | −1.0K | $502.05 | $519.1K |
|---|
| Rossitto Erica · SVP & Chief Nurse Executive | 10 Feb 2026 | Shares withheld for tax | −418 | $502.05 | $209.9K |
|---|
| Rossitto Erica · SVP & Chief Nurse Executive | 10 Feb 2026 | Grant or award | +1.7K | — | — |
|---|
| McAlevey Michael R · EVP & Chief Legal & Admin Off. | 10 Feb 2026 | Grant or award | +8.4K | — | — |
|---|
Form 4 filings since 16 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.
HCA in the terminal
Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.